288 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC)
I/C
PD-1/PDL-1 inhibitors, anti-EGFR agents, cetuximab, panitumumab, control, platinum-resistant disease, methotrexate, platinum-based regimens
O
overall survival (OS), progression-free survival (PFS), overall response rates (ORR)
P
RELAPSED OR REFRACTORY (R/R) AML PATIENTS
I/C
CLAG REGIMEN, CLAG-M REGIMEN, CLAG COMBINED WITH ANY OTHER DRUGS REGIMEN, CLAG RELATED REGIMENS
O
OVERALL RESPONSE RATE (ORR), OVERALL SURVIVAL (OS), EARLY DEATH (ED), ADVERSE EVENTS
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
12,600 participants
I/C
checkpoint inhibitor pneumonitis (CIP), endocrine and skin irAEs, severe-grade irAEs, low-grade irAEs, multiple irAEs, 1 irAE
O
overall survival (OS), objective response rate (ORR)
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
patients with metastatic non-small cell lung cancer
I/C
anti-PD-1 or anti-PD-L1 monotherapy, chemotherapy
O
objective response rate (ORR), 1-year and 2-year progression-free survival (PFS), and 2-year and 3-year overall survival (OS)
P
patients
I/C
immune checkpoint inhibitors (ICIs), biomarker-negative tumours
O
objective response rate (ORR), progression-free survival (PFS), overall survival (OS)
P
mTNBC patients
I/C
PD-1/PD-L1 checkpoint inhibitors, chemotherapy
O
objective response rate (ORR), progression-free survival (PFS), overall survival (OS)